Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy

Is nirsevimab associated with preventing hospitalizations due to respiratory syncytial virus (RSV) among infants at higher risk of severe disease?In this case-control study of 179 RSV-related hospitalizations among at-risk infants, nirsevimab administration was associated with a 79.5% reduction in RSV-related hospitalizations overall among at-risk infants, with estimated reductions of 74.4% among extremely preterm infants and those with congenital heart disease and 87.6% among infants with congenital heart disease alone.These findings suggest that universal immunization with nirsevimab may substantially reduce RSV-related hospitalizations among high-risk infants, supporting replacement of targeted palivizumab prophylaxis with a broader nirsevimab strategy.

Corresponding Author: Leonardo J. Basso, PhD, Industrial Engineering Department, Universidad de Chile, Av Beauchef 851, 8370456, Santiago, Chile (lbasso@uchile.cl).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.